Laura A. Navalta leads Clinical Operations at Elion Therapeutics. Her extensive background in drug development, coupled with strong knowledge and passion in the clinical operations arena, make Laura a powerhouse for the company. Laura has nearly 40 years of industry experience, with global expertise in all phases of clinical trial start-up, oversight, vendor selection & management, quality compliance, as well as regulatory requirements. In addition to infectious disease, Laura’s experience covers a breadth of therapeutic areas, including oncology, cardiovascular & renal, critical care areas, and neurology. Most recently, Laura has held senior executive roles in clinical operations for pharmaceutical & biotechnology organizations, providing critical contributions to multiple drug approvals, including Rezzayo® (2023) for the treatment of candidemia and invasive candidiasis.